Indivior Pharmaceuticals (INDV) Operating Expenses (2024 - 2026)

Indivior Pharmaceuticals' Operating Expenses history runs 3 years deep, the most recent figure standing at $139.0 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 10.9% year-over-year to $139.0 million in Q1 2026; TTM through Mar 2026 was $715.0 million, a 20.99% decrease from a year earlier, with the FY2025 full-year figure at $732.0 million, down 20.35% from the prior year.
• Operating Expenses declined to $139.0 million in Q1 2026 per INDV's latest filing, from $211.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $338.0 million in Q2 2024 and bottomed at $139.0 million in Q1 2026.
• The 3-year median for Operating Expenses is $187.0 million (2025), against an average of $199.0 million.
• Biggest YoY gain for Operating Expenses was 2.93% in 2025; the steepest drop was 47.34% in 2025.
• Year by year, Operating Expenses stood at $205.0 million in 2024, then grew by 2.93% to $211.0 million in 2025, then plunged by 34.12% to $139.0 million in 2026.
• Per Business Quant, the three latest INDV Operating Expenses figures stand at $139.0 million (Q1 2026), $211.0 million (Q4 2025), and $187.0 million (Q3 2025).